Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
INMB on Nasdaq
Shares outstanding
27,094,118
Price per share
$1.56
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
4,653,422
Total reported value
$9,631,501
% of total 13F portfolios
0%
Share change
-972,627
Value change
-$1,934,712
Number of holders
72
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HIGHBRIDGE CAPITAL MANAGEMENT LLC 5.2% $3,490,560 1,454,400 Highbridge Capital Management, LLC 30 Jun 2025
CVI Investments, Inc. 4.9% -10% $3,351,070 -$248,930 1,396,279 -6.9% CVI Investments, Inc. 30 Jun 2025
Praetorian PR LLC 3.4% -54% $2,210,880 -$1,766,400 921,200 -44% Kupperman Harris 30 Jun 2025

As of 30 Sep 2025, 72 institutional investors reported holding 4,653,422 shares of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB). This represents 17% of the company’s total 27,094,118 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) together control 16% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 4.4% 1,186,876 +1.2% 0% $2,456,833
VANGUARD GROUP INC 3.2% 876,292 +3.4% 0% $1,813,924
GEODE CAPITAL MANAGEMENT, LLC 1.7% 469,440 +20% 0% $972,014
STATE STREET CORP 1% 283,833 +3.1% 0% $587,534
RAYMOND JAMES FINANCIAL INC 0.99% 268,460 -19% 0% $555,712
NORTHERN TRUST CORP 0.7% 189,116 +15% 0% $391,470
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.58% 156,954 +687% 0% $324,895
UBS Group AG 0.57% 155,522 -65% 0% $321,930
Westside Investment Management, Inc. 0.38% 103,450 +384% 0.03% $214,150
MORGAN STANLEY 0.28% 75,710 -26% 0% $156,720
DEUTSCHE BANK AG\ 0.23% 61,712 +20749% 0% $127,744
Bank of New York Mellon Corp 0.22% 59,851 -2.8% 0% $123,892
JPMORGAN CHASE & CO 0.21% 57,714 -21% 0% $119,468
JANE STREET GROUP, LLC 0.18% 49,574 0% $102,618
XTX Topco Ltd 0.18% 48,744 -61% 0.01% $100,900
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.15% 41,825 -19% 0% $86,578
Focus Partners Advisor Solutions, LLC 0.15% 40,950 -16% 0% $84,767
GROUP ONE TRADING LLC 0.14% 38,584 0% $79,869
PNC Financial Services Group, Inc. 0.14% 38,387 +1.8% 0% $79,461
BARCLAYS PLC 0.11% 30,006 -21% 0% $62,112
WOLVERINE TRADING, LLC 0.11% 29,193 0% $61,597
Laird Norton Wetherby Trust Company, LLC 0.09% 25,000 -32% 0.01% $51,750
RHUMBLINE ADVISERS 0.08% 22,649 +1.4% 0% $46,875
ALLIANCEBERNSTEIN L.P. 0.08% 21,950 0% 0% $45,437
Cambridge Investment Research Advisors, Inc. 0.08% 21,375 -34% 0% $44,000

Institutional Holders of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 11,181 $17,243 -$53,710 $1.56 3
2025 Q3 4,653,422 $9,631,501 -$1,934,712 $2.07 72
2025 Q2 5,623,690 $12,725,267 -$10,010,251 $2.31 78
2025 Q1 6,162,475 $48,114,616 -$163,537 $7.81 81
2024 Q4 6,169,914 $28,816,114 +$2,159,837 $4.67 71
2024 Q3 5,352,153 $28,835,055 +$6,023,573 $5.39 66
2024 Q2 4,566,933 $40,279,503 +$15,412,568 $8.82 56
2024 Q1 2,738,821 $32,179,382 +$4,840,976 $11.75 50
2023 Q4 2,233,931 $25,153,434 +$1,923,959 $11.26 45
2023 Q3 2,060,286 $13,982,618 +$741,995 $6.77 34
2023 Q2 2,004,530 $18,202,736 +$1,885,158 $9.08 30
2023 Q1 1,802,803 $11,645,317 +$1,101,429 $6.46 30
2022 Q4 1,645,007 $10,428,171 -$728,830 $6.34 31
2022 Q3 1,912,170 $11,854,300 -$743,308 $6.20 30
2022 Q2 1,996,947 $17,510,000 -$2,197,752 $8.83 32
2022 Q1 2,279,692 $19,193,000 -$2,106,647 $8.42 30
2021 Q4 2,472,720 $25,222,000 +$4,967,949 $10.20 40
2021 Q3 1,912,068 $37,112,840 +$3,976,707 $19.42 38
2021 Q2 1,726,817 $30,432,000 +$8,490,513 $17.57 38
2021 Q1 1,305,363 $15,487,940 +$5,449,238 $11.88 31
2020 Q4 792,296 $13,641,000 +$1,188,174 $17.20 23
2020 Q3 991,941 $10,244,000 +$6,455,400 $10.30 26
2020 Q2 358,561 $1,881,000 +$106,639 $5.17 11
2020 Q1 341,483 $1,137,000 +$198,616 $3.33 8
2019 Q4 282,367 $1,637,000 +$40,401 $5.80 9
2019 Q3 274,538 $1,620,000 +$1,389,336 $5.90 9
2019 Q2 35,672 $346,000 -$68,203 $9.85 6
2019 Q1 44,733 $350,000 +$350,001 $7.83 3